glp 1 saxenda (liraglutide) for the Treatment of Obesity, US Saxenda (liraglutide)

However, the wording in Section 8.134 has been interpreted inconsistently around the verification of the suppliers sterility assurance

and R01-DK118725 and R01-DK088423 to J.K.E

Medical Evaluation, Biomarkers, and Appropriate GLP-1 Candidate Selection Specialty drug classification reflects insurance recognition that GLP-1 medications require appropriate patient selection

While this doesnt negate their metabolic benefits, it highlights a crucial aspect of long-term patient care

The generic GLP-1 approval from the US Food and Drug Administration (FDA) is for Teva Pharmaceuticals version of Novo Nordisks injectable Saxenda (liraglutide)